- Login
- Register & Subscribe
- Langue: EN FR DE
Friday 3 February 2012
Carolyn Compton
Carolyn Compton, a senior scientist, has been appointed president and chief executive officer of the Critical Path Institute (C-Path) in Tucson, Arizona, US, taking over from the institute&rs
Country: United States
Monday 23 January 2012
John Perkins
John Perkins, CBE, has been appointed as the chief scientific advisor to the UK government’s Department for Business, Innovation and Skills, whose key objectives are to stimulate economic gro
Country: United Kingdom
Wednesday 11 January 2012
Briggs Morrison
Briggs Morrison, a pharmaceutical industry veteran, has been appointed to the position of executive vice president for global medicines development at AstraZeneca, succeeding Anders Ekblom.
Country: United Kingdom
Wednesday 4 January 2012
Russell Greig
Russell Greig, former president of GlaxoSmithKline’s venture capital arm, has been appointed chair of the supervisory board of AM-Pharma BV of the Netherlands, a company with products in deve
Country: Netherlands
Tuesday 3 January 2012
Mark Bodmer
Mark Bodmer, a former executive at GlaxoSmithKline Plc, has joined UCB SA as vice president and head of immunology at the Belgian company’s new medicines unit.
Country: Belgium
Sunday 1 January 2012
Peter Theil
Peter Theil, a former Genentech executive, has joined UCB SA as vice president and head of non-clinical development for new medicines.
Country: Belgium
Sunday 1 January 2012
Thomas Szucs
Thomas Szucs, professor of pharmaceutical medicine at the University of Basel, has been elected chair of the supervisory board of Intercell AG.
Country: Austria
Thursday 29 December 2011
Michele Antonelli
Michele Antonelli is to become executive vice president and managing director of UCB France on 1 January 2012 following a change in the composition of the Belgian company’s executive com
Country: Belgium
Wednesday 28 December 2011
Sophie Kornowski-Bonnet
The Roche group has appointed Sophie Kornowski-Bonnet to the position of head of partnering, effective 1 February 2012, succeeding Dan Zabrowski.
Country: Switzerland
Saturday 24 December 2011
Peter Gruss
Peter Gruss, president of the Max Planck Society, has been nominated to join the board of directors of Actelion Pharmaceuticals Ltd, a Swiss-based biopharmaceutical company.
Country: Switzerland
Friday February 3 2012
Monday January 23 2012
Wednesday January 11 2012
Wednesday January 4 2012
Tuesday January 3 2012